{
    "clinical_study": {
        "@rank": "95647", 
        "acronym": "BRP", 
        "arm_group": {
            "arm_group_label": "Subconjunctival Bevacizumab", 
            "arm_group_type": "Experimental", 
            "description": "One aplication of subconjunctival Bevacizumab 0,5 ml"
        }, 
        "brief_summary": {
            "textblock": "A study to research whether subconjunctival bevacizumab injection may potentially suppress\n      neovascularization in pterygium, retarding and decreasing the size of recurrent pterygium."
        }, 
        "brief_title": "Subconjunctival Bevacizumab and Recurrent Pterygium", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Recurrent Pterygium", 
        "condition_browse": {
            "mesh_term": "Pterygium"
        }, 
        "detailed_description": {
            "textblock": "1. Pacients with recurrent pterygium\n\n        2. Anti-VEGF therapy -Bevacizumab"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Recurrent pterygium\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  History of myocardial infarction\n\n          -  History of stroke"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744756", 
            "org_study_id": "pterygium bevacizumab"
        }, 
        "intervention": {
            "arm_group_label": "Subconjunctival Bevacizumab", 
            "description": "One subconjunctival aplication of Bevacizumabe 0,5ml", 
            "intervention_name": "Bevacizumab", 
            "intervention_type": "Drug", 
            "other_name": "Avastin"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Subconjunctival Bevacizumab", 
            "Recurrent pterygium"
        ], 
        "lastchanged_date": "December 6, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Goiania", 
                    "country": "Brazil", 
                    "state": "Goias", 
                    "zip": "74110120"
                }, 
                "name": "Instituto de Olhos de Goiania"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium", 
        "overall_official": {
            "affiliation": "Instituto de Olhos de Goiania", 
            "last_name": "Larissa S Stival, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "-Size of recurrent pterygium (measured in mm) after injection", 
            "measure": "Pterygium size after subconjunctival bevacizumab", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744756"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "-Number of patients with hyposphagma and irritative symptoms after subconjunctival injection", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "source": "Instituto de Olhos de Goiania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto de Olhos de Goiania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}